Navigation Links
Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
Date:5/13/2008

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) today reported its financial results for the third quarter ended March 31, 2008 and announced new strategic objectives as part of a restructuring of its clinical-stage product portfolio and development programs. Palatin will continue to develop products targeting melanocortin and natriuretic receptors in the sexual dysfunction, obesity, and cardiovascular fields, including acute hospital care products for use in treatment of acute systemic hypertension, congestive heart failure and hemorrhagic shock. The restructuring focuses the Company's resources on the programs and opportunities that management believes are most likely to increase shareholder value. Additional details will be provided by management in a conference call today at 11:00 a.m. Eastern Time.

Strategic Restructuring

Palatin has undertaken a strategic restructuring with the following elements and objectives:

-- Following a detailed evaluation, including review of regulatory and

commercial information and data on its new melanocortin compounds under

development for sexual dysfunction, Palatin has discontinued

development of bremelanotide for the treatment of male and female

sexual dysfunction;

-- Developing bremelanotide as a therapeutic drug for treatment of

hemorrhagic shock and related indications (shock induced by blood loss,

such as secondary to surgery or trauma);

-- Initiating a Phase 2A study this quarter with PL-3994, Palatin's

natriuretic peptide receptor A agonist compound, in patients with

controlled hypertension;

-- Initiating a Phase 2A study of PL-3994 durin
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
2. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
3. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
4. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
5. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
7. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
8. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
9. Veran Medical Technologies Secures $4.75M in First Institutional Funding
10. Neurobiological Technologies Reports Third Quarter Financial Results
11. InSet Technologies Appoints Jon Tremmel to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell Lindgren ... month on his first mission to the International Space ... 8 to 9 a.m. EDT Tuesday, July 7. ... Star City, Russia . The interviews will ... Television highlighting his mission training. To schedule an ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2
... Ill. University of Illinois engineers have developed ... that could shrink integrated circuits and expand microelectronics. ... multiple transistors and electronic components together to perform ... boards traditionally are made from pre-fabricated metal wires ...
... ,, NEW YORK , July 15 Senesco Technologies (NYSE Amex: SNT ) announces the following ... What:  LHA Life Sciences & Med Tech Day 2010 Presentation , , ... Eastern , , , ... How:  Live over the Internet -- Simply log on to the web at the ...
... , QUEBEC CITY , July 14 ... TSX: AEZ) (the "Company"), a late-stage drug development ... announced that its partner, Keryx Biopharmaceuticals, Inc. ("Keryx") ... the U.S. Food and Drug Administration ("FDA") for ...
Cached Biology Technology:Small wires make big connections for microelectronics 2Small wires make big connections for microelectronics 3Webcast Alert: Senesco Technologies (SNT) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation 2Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 2Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 3Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 4
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... network known to date in the plant kingdom has ... the Danforth Plant Science Center. The results of ... elaborate heterotirmeric G-protein family from soybean expands the diversity ... G-proteins are signaling proteins that direct a plant,s ...
... of Medicine have found that exposure during pregnancy to ... cognitive development. The findings are published online in ... 2002, the Mount Sinai Children,s Environmental Health Study enrolled ... their third trimester of pregnancy. The research team collected ...
... (Boston) A pulse oximetry training video produced ... for the department of anesthesiology at Boston Medical Center ... of Medicine (BUSM), and his colleagues is featured in ... The training video, which is the fifth ...
Cached Biology News:Prenatal exposure to certain pesticides may negatively impact cognitive development in children 2Pulse oximetry training video by BMC anesthesiologist published in NEJM 2
... for the synthesis of 5' capped RNA ... of cap analog for a large portion ... transcription reaction results in the incorporation of ... of the transcripts. Capped mRNAs are generally ...
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. iEMS Incubator/Shaker ... one-cabinet model, allowing the capacity ...
... structure called a ?cap? is present ... eukaryotic mRNAs and many viral RNAs. ... portion of the GTP present in ... in the synthesis of transcripts with ...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
Biology Products: